-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly to Buy US-listed AtaiBeckley in Up to $3.8 Billion Deal

MT Newswires·07/16/2026 07:40:29
Listen to the news
07:40 AM EDT, 07/16/2026 (MT Newswires) -- Eli Lilly (LLY.SW, LLY.F) agreed to acquire US-listed rapid-acting neuroplastogens developer AtaiBeckley for an upfront cash consideration of $6.75 per share. The deal represents an equity value of $2.8 billion and includes an additional potential consideration of $2.50 per share, or $1 billion, in the form of a contingent value right, the pharmaceutical giant said Thursday. Subject to approval by AtaiBeckley's shareholders and regulatory clearances, the deal is expected to close in the third quarter.